Table 3.
Norepinephrine dose before and first reported after CytoSorb® treatment; MAP levels before and 24 h after CytoSorb® treatment (difference: treatment group—control group)
| Norepinephrine (µg/kg/min) before treatment | Norepinephrine (µg/kg/min) after treatment | MAP (mmHg) before treatment | MAP (mmHg) 24 h after treatment | |||||
|---|---|---|---|---|---|---|---|---|
| M ± SD | Md [IQR] | M ± SD | Md [IQR] | M ± SD | Md [IQR] | M ± SD | Md [IQR] | |
| Sepsis | 0.03 (± 0.25) | 0.05 [− 0.21; 0.31] | 0.00 (± 0.15) | 0.02 [− 0.11; 0.14] | 2.07 (± 9.31) | 1.81 [− 7.18; 10.80] | ||
| CPB surgery | 0.01 (± 0.01) | 0.01 [− 0.01; 0.02] | 1.64 (± 2.79) | 2.44 [− 0.61; 5.49] | ||||
| Severe illness | ||||||||
| SARS-CoV-2 | − 0.03 (± 0.07) | − 0.02 [− 0.06; 0.02] | − 0.01 (± 0.04) | − 0.04 [− 0.10; 0.03] | ||||
| Cardiac arrest | − 0.16 (± 0.15) | − 0.09 [− 0.35; 0.18] | ||||||
| All studies | − 0.02 (± 0.06) | − 0.02 [− 0.08; 0.04] | 0.00 (± 0.02) | − 0.01 [− 0.02; 0.01] | 1.51 (± 5.61) | 1.12 [− 4.73; 6.97] | 1.17 (± 2.65) | 1.80 [− 1.07; 4.66] |
Only the mean difference shown in bold was significant at the 0.05 level. Otherwise no statistically significant differences occurred